scispace - formally typeset
T

Timothy Petersen

Researcher at University of New Mexico

Publications -  126
Citations -  4487

Timothy Petersen is an academic researcher from University of New Mexico. The author has contributed to research in topics: Major depressive disorder & Depression (differential diagnoses). The author has an hindex of 37, co-authored 117 publications receiving 4041 citations. Previous affiliations of Timothy Petersen include University of New Mexico Hospital & Harvard University.

Papers
More filters
Journal ArticleDOI

Quality of life assessments in major depressive disorder: a review of the literature.

TL;DR: A number of studies report poorer quality of life in MDD patients compared to controls, and trials comparing the role of newer psychopharmacologic agents in the acute phase of treatment, and the roleof newer psychotherapies in the continuation and maintenance phases of treatment are lacking, to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care.
Journal ArticleDOI

Complications in Pediatric Regional Anesthesia: An Analysis of More than 100,000 Blocks from the Pediatric Regional Anesthesia Network.

Benjamin J. Walker, +55 more
- 01 Oct 2018 - 
TL;DR: A level of safety in pediatric regional anesthesia that is comparable to adult practice and confirms the safety of placing blocks under general anesthesia in children is demonstrated.
Journal ArticleDOI

Should More Patients Continue Aspirin Therapy Perioperatively?: Clinical Impact of Aspirin Withdrawal Syndrome

TL;DR: Clinicians should employ a patient-specific strategy for perioperative aspirin management that weighs the risks of stopping aspirin with those associated with its continuation, as compared with the concomitant thromboembolic risks associated with aspirin withdrawal.
Journal ArticleDOI

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.

TL;DR: A possible augmentation role for ziprasidone when used in conjunction with SSRIs in SSRI-resistant MDD is suggested, with no clinically significant QTc prolongation or severe adverse events observed in any of the study participants.
Journal ArticleDOI

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.

TL;DR: A possible augmentation role for aripiprazole when used in conjunction with SSRIs in SSRI-resistant MDD is suggested, and no severe adverse events were observed in any of the study participants.